We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Neogen Stock Rallies 83% YTD: What's Driving the Surge?
Read MoreHide Full Article
Key Takeaways
Neogen's Food Safety revenues rose 3.1%, with core growth reaching 5.8% in fiscal 2026's fourth quarter.
Petrifilm remains a key asset as Neogen brings manufacturing in-house and expands its product platform.
Neogen plans to boost fiscal 2027 R&D spending 50%, targeting pathogen detection and sanitation platforms.
Neogen (NEOG - Free Report) shares have shown impressive momentum so far this year, surging 83%. The stock has outpaced the industry’s 21.6% fall and the S&P 500 composite’s 11.7% rise.
Carrying a Zacks Rank #2 (Buy) at present, the company’s Food Safety strength and solutions-based selling strategy are supporting growth momentum and portfolio expansion. Neogen is expanding its product and manufacturing capabilities following the 3M Food Safety combination, with Petrifilm playing a key role. It also continues to expand its product pipeline with new launches and differentiated technologies.
Neogen develops, manufactures and markets a diverse line of products and services dedicated to food and animal safety. The company’s Food Safety segment markets diagnostic solutions, test kits, culture media and complementary products used to detect foodborne pathogens, natural toxins, allergens and sanitation concerns. Its Animal Safety portfolio includes life sciences products, veterinary instruments and disposables, animal care products, pest control solutions and genomics services. In March 2026, Neogen agreed to sell its Genomics business to Zoetis for $160 million, subject to regulatory approvals and customary closing conditions.
Factors Supporting NEOG’s Price Rally
The rally in the company’s share price can be linked to the continued momentum in Neogen’s Food Safety segment, its central growth engine, which is supported by a broad portfolio spanning indicator testing, culture media, pathogen detection and sanitation. In the fourth quarter of fiscal 2026, segment revenues jumped 3.1% year over year, while core growth reached 5.8%, the highest quarterly rate since fiscal 2023. Indicator Testing and Culture Media revenues rose 9.5%, while Bacterial and General Sanitation increased 9.9%.
Image Source: Zacks Investment Research
The company is also shifting toward global solutions-based selling, with resources focused on strategic accounts, disciplined segmentation and higher-return geographies. Management expects this model to deepen portfolio penetration and improve customer engagement.
Neogen’s 2022 combination with 3M’s Food Safety business continues to expand its product breadth and manufacturing capabilities, with Petrifilm remaining a key strategic asset. The company is bringing Petrifilm manufacturing in-house at its Lansing facility. The new manufacturing platform is also designed to support broader innovation, including additional Petrifilm SKUs and expansion into pharmaceuticals, nutraceuticals and consumer products.
Neogen continues to expand its product pipeline across Food and Animal Safety while directing more resources toward differentiated technologies. Recent launches include Neogen MPNTray, the Listeria Right Now molecular detection assay, Igenity BCHF and MDA2 Quantitative Salmonella. Listeria Right Now received AOAC Performance Tested Methods certification in fiscal 2026, supporting broader commercial use of the enrichment-free environmental monitoring test.
Strategically, the company is advancing a three-part transformation centered on commercial execution, innovation and operational efficiency. The commercial program is moving from local product-led selling toward a global solutions-based model, with sales resources being realigned around priority countries, customer segments and strategic accounts. Neogen expects fiscal 2027 research and development (R&D) spending to rise about 50% from fiscal 2026, focused on Petrifilm, informatics, technology licensing and next-generation platforms in pathogen detection and general sanitation.
What Ails NEOG?
Historically, Neogen has faced intense competition resulting from the development of new technologies by the company’s competitors, which could affect the marketability and profitability of its products. It also remains materially exposed to foreign currency fluctuations, with international sales accounting for 51.2% of fiscal 2026 revenues.
A Glance at NEOG’s Estimates
The Zacks Consensus Estimate for NEOG’s fiscal 2027 earnings per share (EPS) is expected to drop 3.1% from 2026 to 31 cents. In the past 60 days, the estimate has risen 1 cent. Meanwhile, fiscal 2028 EPS is projected to grow 17.2% to 36 cents.
The company’s fiscal 2027 revenues are projected to rise 1.5% to $883.2 million, while fiscal 2028 revenues are expected to fall 4.2% to $846.5 million.
Veracyte has an earnings yield of 4.7% against the industry’s negative 1.4% yield. Shares of the company have risen 29.1% compared with the industry’s 8.2% growth. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%.
Phibro Animal Health, sporting a Zacks Rank #1, has an earnings yield of 10.2% compared with the industry’s 2.5% yield. Its earnings beat estimates in each of the trailing four quarters, the average surprise being 18.4%. PAHC shares have fallen 8.2% against the industry’s 27.7% decline over the past year.
Globus Medical, sporting a Zacks Rank #1, has an earnings yield of 6.8% against the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED shares have rallied 29% compared with the industry’s 8.3% growth over the past year.
View the Zacks #1 Rank List
Image: Bigstock
Neogen Stock Rallies 83% YTD: What's Driving the Surge?
Key Takeaways
Neogen (NEOG - Free Report) shares have shown impressive momentum so far this year, surging 83%. The stock has outpaced the industry’s 21.6% fall and the S&P 500 composite’s 11.7% rise.
Carrying a Zacks Rank #2 (Buy) at present, the company’s Food Safety strength and solutions-based selling strategy are supporting growth momentum and portfolio expansion. Neogen is expanding its product and manufacturing capabilities following the 3M Food Safety combination, with Petrifilm playing a key role. It also continues to expand its product pipeline with new launches and differentiated technologies.
Neogen develops, manufactures and markets a diverse line of products and services dedicated to food and animal safety. The company’s Food Safety segment markets diagnostic solutions, test kits, culture media and complementary products used to detect foodborne pathogens, natural toxins, allergens and sanitation concerns. Its Animal Safety portfolio includes life sciences products, veterinary instruments and disposables, animal care products, pest control solutions and genomics services. In March 2026, Neogen agreed to sell its Genomics business to Zoetis for $160 million, subject to regulatory approvals and customary closing conditions.
Factors Supporting NEOG’s Price Rally
The rally in the company’s share price can be linked to the continued momentum in Neogen’s Food Safety segment, its central growth engine, which is supported by a broad portfolio spanning indicator testing, culture media, pathogen detection and sanitation. In the fourth quarter of fiscal 2026, segment revenues jumped 3.1% year over year, while core growth reached 5.8%, the highest quarterly rate since fiscal 2023. Indicator Testing and Culture Media revenues rose 9.5%, while Bacterial and General Sanitation increased 9.9%.
Image Source: Zacks Investment Research
The company is also shifting toward global solutions-based selling, with resources focused on strategic accounts, disciplined segmentation and higher-return geographies. Management expects this model to deepen portfolio penetration and improve customer engagement.
Neogen’s 2022 combination with 3M’s Food Safety business continues to expand its product breadth and manufacturing capabilities, with Petrifilm remaining a key strategic asset. The company is bringing Petrifilm manufacturing in-house at its Lansing facility. The new manufacturing platform is also designed to support broader innovation, including additional Petrifilm SKUs and expansion into pharmaceuticals, nutraceuticals and consumer products.
Neogen continues to expand its product pipeline across Food and Animal Safety while directing more resources toward differentiated technologies. Recent launches include Neogen MPNTray, the Listeria Right Now molecular detection assay, Igenity BCHF and MDA2 Quantitative Salmonella. Listeria Right Now received AOAC Performance Tested Methods certification in fiscal 2026, supporting broader commercial use of the enrichment-free environmental monitoring test.
Strategically, the company is advancing a three-part transformation centered on commercial execution, innovation and operational efficiency. The commercial program is moving from local product-led selling toward a global solutions-based model, with sales resources being realigned around priority countries, customer segments and strategic accounts. Neogen expects fiscal 2027 research and development (R&D) spending to rise about 50% from fiscal 2026, focused on Petrifilm, informatics, technology licensing and next-generation platforms in pathogen detection and general sanitation.
What Ails NEOG?
Historically, Neogen has faced intense competition resulting from the development of new technologies by the company’s competitors, which could affect the marketability and profitability of its products. It also remains materially exposed to foreign currency fluctuations, with international sales accounting for 51.2% of fiscal 2026 revenues.
A Glance at NEOG’s Estimates
The Zacks Consensus Estimate for NEOG’s fiscal 2027 earnings per share (EPS) is expected to drop 3.1% from 2026 to 31 cents. In the past 60 days, the estimate has risen 1 cent. Meanwhile, fiscal 2028 EPS is projected to grow 17.2% to 36 cents.
The company’s fiscal 2027 revenues are projected to rise 1.5% to $883.2 million, while fiscal 2028 revenues are expected to fall 4.2% to $846.5 million.
Other Key Picks
Some other top-ranked stocks in the broader medical space are Veracyte (VCYT - Free Report) , Phibro Animal Health (PAHC - Free Report) and Globus Medical (GMED - Free Report) .
Veracyte has an earnings yield of 4.7% against the industry’s negative 1.4% yield. Shares of the company have risen 29.1% compared with the industry’s 8.2% growth. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%.
VCYT sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Phibro Animal Health, sporting a Zacks Rank #1, has an earnings yield of 10.2% compared with the industry’s 2.5% yield. Its earnings beat estimates in each of the trailing four quarters, the average surprise being 18.4%. PAHC shares have fallen 8.2% against the industry’s 27.7% decline over the past year.
Globus Medical, sporting a Zacks Rank #1, has an earnings yield of 6.8% against the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED shares have rallied 29% compared with the industry’s 8.3% growth over the past year.